



EFA Session during the 27th EADV Conference on September 13, 2018
from 17h00-18h00

Room 243, 2nd floor

Atopic Eczema - the silent suffering of patients

17:00	Welcome and set the scene	Carla Jones, United Kingdom
17:05	EFA Atopic Eczema Survey: Outline and Key results	Johannes Ring, Germany
17:20	Patients interpretation of the survey results	Bernd Arents, Netherlands
17:40	Panel Discussion: breaking away atypical lives	All above plus Carle Paul, France Jean Paul Stahl, France Alice Visintin, Italy
17:55	Conclusion	Carla Jones, United Kingdom

Background

The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) ran the first study of this size in Europe (n= 1189 adult patients with severe atopic eczema from nine EU countries) that assesses the real world impact and the intensity of individual suffering in the daily living of eczema patients.

Objective

To provide insight on the burden of disease and quality of life of adult patients with severe atopic eczema (AE) in a real world setting, as to create awareness and understanding for this severe disease within healthcare professionals (dermatologists, allergists, primary-care-physicians, nurses, pharmacists), health journalists, patient organisations, patients and their families and EU policy makers including payers.

Content and speakers introduction

Carla Jones, CEO of Allergy UK and Board Member of EFA will serve as moderator.

The survey methodology and key results are presented by **Johannes Ring**, Professor and Chairman of the Department of Dermatology and Allergology, Biederstein of the Technische Universität München, Munich, Bavaria, Germany. He received his training at the Ludwig-Maximilians University in immunology and dermato-venereology under Professor Otto Braun-Falco, before he became Director and Chairman of the Department of Dermatology of the University of Hamburg (1990-1995). He has served on the board of directors or as president many national and international societies, including the European Society for Dermatological Research (ISDR), the European Academy of Dermatology and Venereology (EADV), and the Collegium Internationale Allergologicum (CIA). His special interests include clinical dermatology and allergy, environmental medicine, and novel therapeutic aspects.

The interpretation of the survey results by patients will be given by **Bernd Arents**, a severe atopic eczema patient since birth. In 1996, he began volunteering at the Association for People with Atopic Dermatitis (VMCE) in the Netherlands. Since 2003, he has been a part of VMCE's leadership focusing on the quality of eczema care. He is a member of the Authorisation Committee Guidelines of the Dutch Society for Dermatology and Venereology, a patient reviewer for medical journals (BMJ, Br.J. Derm. and JEADV) and the European Medicines Agency. He is co-author of the recently published Cochrane systematic review 'Emollients and moisturisers in eczema'.

Professor **Carle Paul** is the current EADV President Elect and works at Paul Sabatier University - Toulouse III and CHU Toulouse. Carle chairs the Department of Dermatology and Allergology.

Professor **Jean Paul Stahl** teaches Infectious Diseases, University Hospital, Grenoble, France. He is also Head of Infections Department. Previous President of the French Infectious Diseases Society and Member of a group in the French Health Ministry about antibiotic stewardship.

Alice Visintin is an atopic eczema patient and a physician and coordinator of scientific committees of ANDeA, the Italian Atopic Dermatitis patient's association, member of the Italian Federation of Allergy and Asthma.